The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways
Open accessAbstract
Gene-expression profiling has been used to define 3 molecular subtypes of diffuse large B-cell lymphoma (DLBCL), termed germinal center B-cell-like (GCB) DLBCL, activated B-cell-like (ABC) DLBCL, and primary mediastinal B-cell lymphoma (PMBL). To investigate whether these DLBCL subtypes arise by distinct pathogenetic mechanisms, we analyzed 203 DLBCL biopsy samples by high-resolution, genome-wide copy number analysis coupled with gene-expression profiling. Of 272 recurrent chromosomal aberrations that were associated with gene-expression alterations, 30 were used differentially by the DLBCL subtypes ( P < 0.006). An amplicon on chromosome 19 was detected in 26% of ABC DLBCLs but in only 3% of GCB DLBCLs and PMBLs. A highly up-regulated gene in this amplicon was SPIB , which encodes an ETS family transcription factor. Knockdown of SPIB by RNA interference was toxic to ABC DLBCL cell lines but not to GCB DLBCL, PMBL, or myeloma cell lines, strongly implicating SPIB as an oncogene involved in the pathogenesis of ABC DLBCL. Deletion of the INK4a / ARF tumor suppressor locus and trisomy 3 also occurred almost exclusively in ABC DLBCLs and was associated with inferior outcome within this subtype. FOXP1 emerged as a potential oncogene in ABC DLBCL that was up-regulated by trisomy 3 and by more focal high-level amplifications. In GCB DLBCL, amplification of the oncogenic mir-17–92 microRNA cluster and deletion of the tumor suppressor PTEN were recurrent, but these events did not occur in ABC DLBCL. Together, these data provide genetic evidence that the DLBCL subtypes are distinct diseases that use different oncogenic pathways.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
Alizadeh, A. A., Eisen, M. B., Davis, R. E., Ma, C., Lossos, I. S., Rosenwald, A., Boldrick, J. C., Sabet, H., Tran, T., Yu, X., et al. (2000) · Nature · doi:10.1038/35000501 · Cited by 9,925
Self-citationGlobal variation in copy number in the human genome
Redon, R., Ishikawa, S., Fitch, K. R., Feuk, L., Perry, G. H., Andrews, T. D., Fiegler, H., Shapero, M. H., Carson, A. R., Chen, W., et al. (2006) · Nature · doi:10.1038/nature05329 · Cited by 4,288
Rosenwald, A., Wright, G., Chan, W. C., Connors, J. M., Campo, E., Fisher, R. I., Gascoyne, R. D., Muller-Hermelink, H. K., Smeland, E. B., Giltnane, J. M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012914 · Cited by 3,829
Self-citationThe Non-Hodgkin's Lymphoma Classification Project (1997) · Blood · doi:10.1182/blood.v89.11.3909 · Cited by 2,461
c-Myc-regulated microRNAs modulate E2F1 expression
O'Donnell, K. A., Wentzel, E. A., Zeller, K. I., Dang, C. V., & Mendell, J. T. (2005) · Nature · doi:10.1038/nature03677 · Cited by 2,347
Rosenwald, A., Wright, G., Leroy, K., Yu, X., Gaulard, P., Gascoyne, R. D., Chan, W. C., Zhao, T., Haioun, C., Greiner, T. C., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20031074 · Cited by 1,101
Self-citationDavis, R. E., Brown, K. D., Siebenlist, U., & Staudt, L. M. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.12.1861 · Cited by 1,051
Self-citationWright, G., Tan, B., Rosenwald, A., Hurt, E. H., Wiestner, A., & Staudt, L. M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1732008100 · Cited by 1,040
Self-citationA Biologic Definition of Burkitt's Lymphoma from Transcriptional and Genomic Profiling
Hummel, M., Bentink, S., Berger, H., Klapper, W., Wessendorf, S., Barth, T. F. E., Bernd, H.-W., Cogliatti, S. B., Dierlamm, J., Feller, A. C., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055351 · Cited by 1,006
Self-citationHigh-throughput oncogene mutation profiling in human cancer
Thomas, R. K., Baker, A. C., DeBiasi, R. M., Winckler, W., LaFramboise, T., Lin, W. M., Wang, M., Feng, W., Zander, T., MacConaill, L. E., et al. (2007) · Nature Genetics · doi:10.1038/ng1975 · Cited by 988
Cited by
Chapuy, B., Stewart, C., Dunford, A. J., Kim, J., Kamburov, A., Redd, R. A., Lawrence, M. S., Roemer, M. G. M., Li, A. J., Ziepert, M., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0016-8 · Cited by 1,941
Self-citationFrequent mutation of histone-modifying genes in non-Hodgkin lymphoma
Morin, R. D., Mendez-Lago, M., Mungall, A. J., Goya, R., Mungall, K. L., Corbett, R. D., Johnson, N. A., Severson, T. M., Chiu, R., Field, M., et al. (2011) · Nature · doi:10.1038/nature10351 · Cited by 1,614
Self-citationMulti-omics Data Integration, Interpretation, and Its Application
Subramanian, I., Verma, S., Kumar, S., Jere, A., & Anamika, K. (2020) · Bioinformatics and Biology Insights · doi:10.1177/1177932219899051 · Cited by 1,609
Oncogenically active MYD88 mutations in human lymphoma
Ngo, V. N., Young, R. M., Schmitz, R., Jhavar, S., Xiao, W., Lim, K.-H., Kohlhammer, H., Xu, W., Yang, Y., Zhao, H., et al. (2011) · Nature · doi:10.1038/nature09671 · Cited by 1,512
Self-citationWright, G. W., Huang, D. W., Phelan, J. D., Coulibaly, Z. A., Roulland, S., Young, R. M., Wang, J. Q., Schmitz, R., Morin, R. D., Tang, J., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.015 · Cited by 1,169
Self-citationAnalysis of the coding genome of diffuse large B-cell lymphoma
Pasqualucci, L., Trifonov, V., Fabbri, G., Ma, J., Rossi, D., Chiarenza, A., Wells, V. A., Grunn, A., Messina, M., Elliot, O., et al. (2011) · Nature Genetics · doi:10.1038/ng.892 · Cited by 971
Tilly, H., Gomes da Silva, M., Vitolo, U., Jack, A., Meignan, M., Lopez-Guillermo, A., Walewski, J., André, M., Johnson, P. W., Pfreundschuh, M., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv304 · Cited by 930
Role of Bruton’s tyrosine kinase in B cells and malignancies
Pal Singh, S., Dammeijer, F., & Hendriks, R. W. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0779-z · Cited by 726
Green, T. M., Young, K. H., Visco, C., Xu-Monette, Z. Y., Orazi, A., Go, R. S., Nielsen, O., Gadeberg, O. V., Mourits-Andersen, T., Frederiksen, M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.4342 · Cited by 686
Hu, S., Xu-Monette, Z. Y., Tzankov, A., Green, T., Wu, L., Balasubramanyam, A., Liu, W.-M., Visco, C., Li, Y., Miranda, R. N., et al. (2013) · Blood · doi:10.1182/blood-2012-10-460063 · Cited by 679
Self-citationAukema, S. M., Siebert, R., Schuuring, E., van Imhoff, G. W., Kluin-Nelemans, H. C., Boerma, E.-J., & Kluin, P. M. (2011) · Blood · doi:10.1182/blood-2010-09-297879 · Cited by 678
Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience
Salles, G., Barrett, M., Foà, R., Maurer, J., O’Brien, S., Valente, N., Wenger, M., & Maloney, D. G. (2017) · Advances in Therapy · doi:10.1007/s12325-017-0612-x · Cited by 620
MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers
Steidl, C., Shah, S. P., Woolcock, B. W., Rui, L., Kawahara, M., Farinha, P., Johnson, N. A., Zhao, Y., Telenius, A., Neriah, S. B., et al. (2011) · Nature · doi:10.1038/nature09754 · Cited by 615
Self-citationAnalysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation
Fabbri, G., Rasi, S., Rossi, D., Trifonov, V., Khiabanian, H., Ma, J., Grunn, A., Fangazio, M., Capello, D., Monti, S., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20110921 · Cited by 610
miR-19 is a key oncogenic component of mir-17-92
Olive, V., Bennett, M. J., Walker, J. C., Ma, C., Jiang, I., Cordon-Cardo, C., Li, Q.-J., Lowe, S. W., Hannon, G. J., & He, L. (2009) · Genes & Development · doi:10.1101/gad.1861409 · Cited by 588
Genetics of Follicular Lymphoma Transformation
Pasqualucci, L., Khiabanian, H., Fangazio, M., Vasishtha, M., Messina, M., Holmes, A. B., Ouillette, P., Trifonov, V., Rossi, D., Tabbò, F., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2013.12.027 · Cited by 573
Sehn, L. H., & Gascoyne, R. D. (2015) · Blood · doi:10.1182/blood-2014-05-577189 · Cited by 560
Self-citationExtensions of Sparse Canonical Correlation Analysis with Applications to Genomic Data
Witten, D. M., & Tibshirani, R. J. (2009) · Statistical Applications in Genetics and Molecular Biology · doi:10.2202/1544-6115.1470 · Cited by 544
Lenz, G., & Staudt, L. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0807082 · Cited by 528
Self-citationExploiting Synthetic Lethality for the Therapy of ABC Diffuse Large B Cell Lymphoma
Yang, Y., Shaffer, A. L., Emre, N. C. T., Ceribelli, M., Zhang, M., Wright, G., Xiao, W., Powell, J., Platig, J., Kohlhammer, H., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.05.024 · Cited by 521
Self-citationGerminal centres and B cell lymphomagenesis
Basso, K., & Dalla-Favera, R. (2015) · Nature Reviews Immunology · doi:10.1038/nri3814 · Cited by 510
Dunleavy, K., Pittaluga, S., Czuczman, M. S., Dave, S. S., Wright, G., Grant, N., Shovlin, M., Jaffe, E. S., Janik, J. E., Staudt, L. M., et al. (2009) · Blood · doi:10.1182/blood-2009-01-199679 · Cited by 497
Self-citationStaudt, L. M. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a000109 · Cited by 485
Self-citationScherer, F., Kurtz, D. M., Newman, A. M., Stehr, H., Craig, A. F. M., Esfahani, M. S., Lovejoy, A. F., Chabon, J. J., Klass, D. M., Liu, C. L., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aai8545 · Cited by 484
Identification of Early Replicating Fragile Sites that Contribute to Genome Instability
Barlow, J. H., Faryabi, R. B., Callén, E., Wong, N., Malhowski, A., Chen, H. T., Gutierrez-Cruz, G., Sun, H.-W., McKinnon, P., Wright, G., et al. (2013) · Cell · doi:10.1016/j.cell.2013.01.006 · Cited by 444
Self-citationPathogenesis of Human B Cell Lymphomas
Shaffer, A. L., Young, R. M., & Staudt, L. M. (2012) · Annual Review of Immunology · doi:10.1146/annurev-immunol-020711-075027 · Cited by 437
Self-citationTargeting B cell receptor signalling in cancer: preclinical and clinical advances
Burger, J. A., & Wiestner, A. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2017.121 · Cited by 431
Vitolo, U., Trněný, M., Belada, D., Burke, J. M., Carella, A. M., Chua, N., Abrisqueta, P., Demeter, J., Flinn, I., Hong, X., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.3402 · Cited by 417
Diffuse large B-cell lymphoma—treatment approaches in the molecular era
Roschewski, M., Staudt, L. M., & Wilson, W. H. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.197 · Cited by 411
Self-citationA multiprotein supercomplex controlling oncogenic signalling in lymphoma
Phelan, J. D., Young, R. M., Webster, D. E., Roulland, S., Wright, G. W., Kasbekar, M., Shaffer, A. L., Ceribelli, M., Wang, J. Q., Schmitz, R., et al. (2018) · Nature · doi:10.1038/s41586-018-0290-0 · Cited by 398
Self-citationMutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing
Morin, R. D., Mungall, K., Pleasance, E., Mungall, A. J., Goya, R., Huff, R. D., Scott, D. W., Ding, J., Roth, A., Chiu, R., et al. (2013) · Blood · doi:10.1182/blood-2013-02-483727 · Cited by 390
Self-citationMathews Griner, L. A., Guha, R., Shinn, P., Young, R. M., Keller, J. M., Liu, D., Goldlust, I. S., Yasgar, A., McKnight, C., Boxer, M. B., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1311846111 · Cited by 377
Self-citationAt the Bench: Preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy
Intlekofer, A. M., & Thompson, C. B. (2013) · Journal of Leukocyte Biology · doi:10.1189/jlb.1212621 · Cited by 371
Visco, C., Li, Y., Xu-Monette, Z. Y., Miranda, R. N., Green, T. M., Li, Y., Tzankov, A., Wen, W., Liu, W.-M., Kahl, B. S., et al. (2012) · Leukemia · doi:10.1038/leu.2012.83 · Cited by 368
Ansell, S. M., Minnema, M. C., Johnson, P., Timmerman, J. M., Armand, P., Shipp, M. A., Rodig, S. J., Ligon, A. H., Roemer, M. G. M., Reddy, N., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00766 · Cited by 353
Ruan, J., Martin, P., Furman, R. R., Lee, S. M., Cheung, K., Vose, J. M., LaCasce, A., Morrison, J., Elstrom, R., Ely, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.1142 · Cited by 319
New insights into pre-BCR and BCR signalling with relevance to B cell malignancies
Rickert, R. C. (2013) · Nature Reviews Immunology · doi:10.1038/nri3487 · Cited by 288
Molecular Pathways: JAK/STAT Pathway: Mutations, Inhibitors, and Resistance
Quintás-Cardama, A., & Verstovsek, S. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0284 · Cited by 284
Cooperative Epigenetic Modulation by Cancer Amplicon Genes
Rui, L., Emre, N. C. T., Kruhlak, M. J., Chung, H.-J., Steidl, C., Slack, G., Wright, G. W., Lenz, G., Ngo, V. N., Shaffer, A. L., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.013 · Cited by 283
Self-citationMandelbaum, J., Bhagat, G., Tang, H., Mo, T., Brahmachary, M., Shen, Q., Chadburn, A., Rajewsky, K., Tarakhovsky, A., Pasqualucci, L., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.10.030 · Cited by 282
Genetics of diffuse large B-cell lymphoma
Pasqualucci, L., & Dalla-Favera, R. (2018) · Blood · doi:10.1182/blood-2017-11-764332 · Cited by 282
Pfeifer, M., Grau, M., Lenze, D., Wenzel, S.-S., Wolf, A., Wollert-Wulf, B., Dietze, K., Nogai, H., Storek, B., Madle, H., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1305656110 · Cited by 270
Self-citationMALT1 Small Molecule Inhibitors Specifically Suppress ABC-DLBCL In Vitro and In Vivo
Fontan, L., Yang, C., Kabaleeswaran, V., Volpon, L., Osborne, M. J., Beltran, E., Garcia, M., Cerchietti, L., Shaknovich, R., Yang, S. N., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.11.003 · Cited by 264
Self-citationChigrinova, E., Rinaldi, A., Kwee, I., Rossi, D., Rancoita, P. M. V., Strefford, J. C., Oscier, D., Stamatopoulos, K., Papadaki, T., Berger, F., et al. (2013) · Blood · doi:10.1182/blood-2013-03-489518 · Cited by 253
Self-citationJanus kinase deregulation in leukemia and lymphoma
Chen, E., Staudt, L. M., & Green, A. R. (2012) · Immunity · doi:10.1016/j.immuni.2012.03.017 · Cited by 123
Self-citationNakhoda, S., Vistarop, A., & Wang, Y. L. (2023) · British Journal of Haematology · doi:10.1111/bjh.18418 · Cited by 104
Green, M. R., Vicente-Dueñas, C., Romero-Camarero, I., Long Liu, C., Dai, B., González-Herrero, I., García-Ramírez, I., Alonso-Escudero, E., Iqbal, J., Chan, W. C., et al. (2014) · Nature Communications · doi:10.1038/ncomms4904 · Cited by 88
Self-citationNovel disease targets and management approaches for diffuse large B-cell lymphoma
Wilson, W. H., Hernandez-Ilizaliturri, F. J., Dunleavy, K., Little, R. F., & O'Connor, O. A. (2010) · Leukemia & Lymphoma · doi:10.3109/10428194.2010.500045 · Cited by 34
Global phosphoproteomic profiling reveals distinct signatures in B-cell non-Hodgkin lymphomas
Rolland, D., Basrur, V., Conlon, K., Wolfe, T., Fermin, D., Nesvizhskii, A. I., Lim, M. S., & Elenitoba-Johnson, K. S. J. (2014) · The American Journal of Pathology · doi:10.1016/j.ajpath.2014.01.036 · Cited by 31
Deep Morphology Learning Enhances Ex Vivo Drug Profiling-Based Precision Medicine
Heinemann, T., Kornauth, C., Severin, Y., Vladimer, G. I., Pemovska, T., Hadzijusufovic, E., Agis, H., Krauth, M.-T., Sperr, W. R., Valent, P., et al. (2022) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-21-0219 · Cited by 28
“3C), despite AMLs and DLBCLs comprising a variety of subtypes (30, 31).”
Background
Metadata
- Authors
- Lenz, G., Wright, G. W., Emre, N. C. T., Kohlhammer, H., Dave, S. S., Davis, R. E., Carty, S., Lam, L. T., Shaffer, A. L., Xiao, W., Powell, J., Rosenwald, A., Ott, G., Muller-Hermelink, H. K., Gascoyne, R. D., Connors, J. M., Campo, E., Jaffe, E. S., Delabie, J., Smeland, E. B., Rimsza, L. M., Fisher, R. I., Weisenburger, D. D., Chan, W. C., & Staudt, L. M.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2008-09-09
- Volume
- 105
- Issue
- 36
- Pages
- 13520-13525
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2030105242
- Cited by
- 995
- References
- 34
- FWCI
- 29.07
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.